Back to Blog

    The experts' perspective on e-cigarettes as an aid to quit smoking

    September 7, 2026
    The experts' perspective on e-cigarettes as an aid to quit smoking

    Helping people who smoke to stop is one of the biggest prizes in US public health because smoking is still the country’s leading cause of preventable death. Advice from the medical profession potentially has a central role in helping to tackle the problem, so it is significant that new recommendations have recently been issued in the US. They advise US clinicians to include e-cigarettes as an option for patients who want to quit smoking and – equally importantly – to correct misperceptions related to the harm and safety of these products.

    Tobacco harm reduction (THR), moving people who smoke to less harmful sources of nicotine, is often dismissed by critics as a tobacco-industry ploy. But the latest advice comes from a working group of the Society for Research on Nicotine and Tobacco (SRNT) – the main scientific society in the field – which published its piece in the prestigious Journal of the American Medical Association (JAMA), accompanied by an editorial from Dr Jamie Hartmann-Boyce.

    The evidence has strengthened

    The last significant US guidance, the American College of Cardiology’s 2018 consensus pathway and the US Preventive Services Task Force’s 2021 review, was written when the evidence base for e-cigarettes was weak, and left clinicians without a current, evidence-based way to discuss e-cigarettes. That has changed markedly: e-cigarettes, the working group writes, “are less harmful than cigarettes and have been shown to be more effective for smoking cessation than … approved nicotine replacement therapies.” The Cochrane living review now finds with high certainty that they outperform NRT; a second review puts them on a par with varenicline, the most effective approved medicine; and a 2026 overview found that all 21 comparisons with other quitting methods favored e-cigarettes, with no trial finding serious harm from using them to quit.

    The central recommendation is thus that for adults who smoke, e-cigarettes should be offered as one of the quitting options, alongside the approved medicines: nicotine-replacement therapies (NRTs, such as patches and gum), varenicline and bupropion. Patients should not have to try and fail on a medication approved by the Food and Drug Administration (FDA) before e-cigarettes are discussed as an option; the point is to get them off cigarettes.

    Correcting misperceptions

    The article also exhorts doctors to correct misperceptions on e-cigarette safety. Many clinicians, and much of the public, now think e-cigarettes are as harmful as cigarettes or worse, a belief which has hardened even as the evidence has moved the other way. Some of that is down to confusion about nicotine, and a belief that it causes disease which is in fact caused by combustion; some is an unintended consequence of anti-youth-vaping campaigns that have, the authors say, confused adults who smoke and for whom e-cigarettes are the less harmful choice; and some is the shadow of the 2019 lung-injury outbreak, caused by illicit cannabis vapes cut with vitamin E acetate, but which got blamed on nicotine e-cigarettes at the time.

    A debate about values, not only evidence

    The accompanying editorial puts the article’s findings in a broader perspective, pointing out that clear evidence hasn’t so far settled controversies in this field because the disagreement is often about values rather than data, “… and that is much harder to untangle.” Harm reduction is broadly accepted elsewhere, including for people who use illicit drugs, but tobacco harm reduction has remained contentious.

    One reason for that is that many in public health remain wary of the industry’s involvement in THR. Another is the concern that a positive press for e-cigarettes might encourage young people to take up vaping. But as Dr Hartmann-Boyce points out, industry involvement and worries about youth do not change the evidence on whether e-cigarettes help people quit. Is the goal eliminating nicotine addiction itself, or the disease burden that smoking causes? If it’s the latter, helping someone who cannot – or doesn’t want to – give up nicotine move to a far less harmful source is the kind of trade-off public health makes in other fields. And any qualms about nicotine itself ought also to apply to NRTs, available on prescription and, for the main forms, over the counter, and which the World Health Organization calls essential medicines.

    US regulation isn’t serving consumers well

    A further recommendation that the authors of the JAMA paper make is that patients should be advised to use e-cigarettes authorized by the FDA, on the basis that the agency will have reviewed their safety and found that placing them on the market is appropriate for the protection of public health. It’s true that FDA authorization ought to give a degree of confidence on product safety and effectiveness, but the problem is that – six years into the current regulatory regime – the FDA has authorized only 48 e-cigarette products for sale.

    Until May 2026 the only flavors available in authorized products were tobacco and menthol; the FDA has now authorized two others, out of 45 products in total, although it is very well documented that adult vapers typically prefer a much wider range of offerings

    Another just-published paper estimates that nearly 70% of e-cigarette products sold in the US grocery and convenience channels were unauthorized as of December 2025.

    Conclusion

    Even if regulation has not yet caught up, it’s very encouraging to us that US guidance on e-cigarettes is moving. The medical profession can play a very important role in increasing the acceptability of these and other products in tobacco harm reduction strategies, and in correcting public misperceptions. And the US remains enormously influential in helping to shape global perceptions; it would be very helpful to have another example alongside the likes of the UK and New Zealand of a country whose health establishment recognizes that e-cigarettes have a legitimate role to play in smoking cessation.

    An investor should consider the investment objectives, risks, and charges and expenses of the fund carefully before investing. A prospectus which contains this and other information about the fund may be obtained by calling 1-800-617-0004, or by clicking here. The prospectus should be read carefully before investing.

    Investing involves risk. Principal loss is possible. The Fund is a recently organized entity, giving prospective investors a limited track record on which to base their investment decision. The Fund’s investments will be concentrated in the securities of issuers in the tobacco, or nicotine-related group of industries. The tobacco industry is subject to significant risks and uncertainties that could materially and adversely affect the financial condition and cash flows, of companies operating in it. Investing in foreign securities typically involves more risks than investing in U.S. securities, and includes risks associated with: (i) internal and external political and economic developments – e.g., the political, economic and social policies and structures of some foreign countries may be less stable and more volatile than those in the U.S. or some foreign countries may be subject to trading restrictions or economic sanctions; (ii) trading practices – e.g., government supervision and regulation of foreign securities and currency markets, trading systems and brokers may be less than in the U.S.; (iii) availability of information – e.g., foreign issuers may not be subject to the same disclosure, accounting and financial reporting standards and practices as U.S. issuers; (iv) limited markets – e.g., the securities of certain foreign issuers may be less liquid (harder to sell) and more volatile; and (v) currency exchange rate fluctuations and policies. Investment in emerging market securities involves greater risk than that associated with investment in securities of issuers in developed foreign countries.

    Derivatives may pose risks in addition to and greater than those associated with investing directly in securities, currencies or other investments, including risks relating to leverage, imperfect correlations with underlying investments or the Fund’s other portfolio holdings, high price volatility, lack of availability, counterparty credit, liquidity, valuation and legal restrictions. A total return swap is a contract in which one party agrees to make periodic payments to another party based on the change in market value of the assets underlying the contract, which may include a specified security, basket of securities, or securities indices during the specified period, in return for periodic payments based on a fixed or variable interest rate or the total return from other underlying assets. The Fund is a non-diversified, investment company under the 1940 Act. Because the Fund is non-diversified, it will invest a greater percentage of its assets in the securities of a limited number of issuers. Investing in medium and small capitalization companies may involve special risks because those companies may have narrower product lines, more limited financial resources, fewer experienced managers, dependence on a few key employees, and a more limited trading market for their stocks, as compared with larger companies. The securities of micro-cap companies may be more volatile in price, have wider spreads between their bid and ask prices, and have significantly lower trading volumes than the securities of larger capitalization companies.

    ETFs are subject to risks that the market price of an ETF's shares may trade at a premium or discount to its net asset value, an active secondary trading market may not develop or be maintained, or trading may be halted by the exchange in which they trade, which may impact an ETF's ability to sell its shares. Shares of any ETF are bought and sold at market price (not NAV) and are not individually redeemed from the ETF. Brokerage commissions will reduce returns.

    The Hexis Nicotine Transition Score (HNTS) is a proprietary framework reflecting the manager’s subjective assessments; independent review by ACA Ethos is not an endorsement of the Fund.

    ETF holdings are subject to change and are not recommendations to buy or sell any security. For current holdings, please click here: Hexis Capital Management | <NICO>

    The Hexis Active Nicotine Engagement ETF is distributed by Quasar Distributors, LLC

    Definitions used on these pages:

    R&D: Research and development spend – investment in developing new products, technologies, or capabilities.

    M&A: Mergers and acquisitions spend – spending on acquiring or merging with other companies to expand scale, capabilities, or market access.

    Capex: Capital expenditure – investment in long-term physical or intangible assets such as facilities, equipment, or infrastructure.

    Discounted Cash Flow (DCF) model – a valuation method that estimates a company’s value by discounting its expected future cash flows back to today.

    Terminal value – the estimated value of a business beyond the explicit forecast period in a DCF model.

    Terminal growth rate – the assumed long-term, steady growth rate used to calculate terminal value.

    EV: Enterprise Value – a measure of a company’s total value, calculated as market capitalisation plus net debt.

    EBITDA: Earnings before interest, taxes, depreciation and amortisation.